Success Metrics

Clinical Success Rate

91.7%

Based on 11 completed trials

Completion Rate

92%(11/12)

Active Trials

1(6%)

Results Posted

27%(3 trials)

Terminated

1(6%)

Phase Distribution

Ph phase_2

22%

Ph phase_1

17%

Ph phase_3

17%

Ph early_phase_1

Ph not_applicable

28%

Ph phase_4

11%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution18 total trials

Early Phase 1First-in-human

1(5.6%)

Phase 1Safety & dosage

3(16.7%)

Phase 2Efficacy & side effects

4(22.2%)

Phase 3Large-scale testing

3(16.7%)

Phase 4Post-market surveillance

2(11.1%)

N/ANon-phased studies

5(27.8%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

73.3%

11 of 15 finished

Non-Completion Rate

26.7%

4 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(1)

Completed(11)

Terminated(4)

Other(2)

Detailed Status

Completed11

Withdrawn3

unknown2

Recruiting1

Terminated1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

91.7%

Most Advanced

Phase 4

Trials by Phase

Early Phase 11 (5.6%)

Phase 13 (16.7%)

Phase 24 (22.2%)

Phase 33 (16.7%)

Phase 42 (11.1%)

N/A5 (27.8%)

Trials by Status

withdrawn317%

completed1161%

unknown211%

recruiting16%

terminated16%

Recent Activity

1 active trials

Showing 5 of 18

completednot_applicable

Comparison of Intravenous Labetalol and Intravenous Hydralazine in Severe Preeclampsia

NCT07572656

recruitingphase_4

Efficacy of Nifedipine Versus Hydralazine in Management of Severe Hypertension in Pregnancy

NCT04435210

View all 18 trials

Clinical Trials (18)

Showing 18 of 18 trials

NCT07572656Not Applicable

Comparison of Intravenous Labetalol and Intravenous Hydralazine in Severe Preeclampsia

Completed

NCT06218199Phase 4

Diuretics vs. Afterload Reduction for Treatment of HeartLogic Alerts

Recruiting

NCT04484350Phase 2

Blood Pressure Management in Stroke Following Endovascular Treatment

Completed

NCT04116112Phase 2

Blood Pressure After Endovascular Stroke Therapy-II

Completed

NCT04435210Not Applicable

Efficacy of Nifedipine Versus Hydralazine in Management of Severe Hypertension in Pregnancy

Completed

NCT03423810Early Phase 1

Assessing a Dose-Response Relationship of Hydralazine and Its Effects on DNA Methyltransferase 1 in Polycystic Kidney Disease Patients

Completed

NCT02050529Phase 2

Randomized Controlled Trial of Labetalol Versus Hydralazine for Severe Hypertension in Obstetric Patients.

Completed

NCT02933593Not Applicable

Changes in Central Arterial Pressure When Comparing ACOG Hypertensive Urgency Protocols

Withdrawn

NCT00223717Phase 1

Treatment of Supine Hypertension in Autonomic Failure

Completed

NCT01822808Phase 3

Bi Treatment With Hydralazine/Nitrates Versus Placebo in Africans Admitted With Acute Heart Failure

Unknown

NCT00575978Phase 1

Hydralazine as Demethylating Agent in Breast Cancer

Withdrawn

NCT00575640Phase 1

Hydralazine as a Demethylating Agent in Rectal Cancer

Withdrawn

NCT02343393Phase 3

Nitrates In Combination With Hydralazine in cardiorEnal Syndrome (NICHE) Study

Unknown

NCT00607477Not Applicable

Pilot Study of the Treatment of Vascular Endothelial Growth Factor(VEGF)Signaling Pathway Inhibitor-Induced Hypertension

Terminated

NCT00000499Phase 2

Systolic Hypertension in the Elderly Program (SHEP) (Pilot Study)

Completed

NCT01538875Phase 3

Hydralazine Versus Labetalol for the Management of Hypertensive Disorders of Pregnancy

Completed

NCT00661895Phase 4

Black Education and Treatment of Hypertension (BEAT HTN)

Completed

NCT00599235Not Applicable

Sildenafil and Exercise Capacity in Hypertension

Completed

All 18 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 18